Key facts
- Wedbush analyst David Windley raised Edgewise Therapeutics' stock price target to $34.
- The previous price target was $20.
- The price target increase is linked to a new partnership with Servier.
- The Servier partnership includes an upfront payment.
- The partnership also includes potential milestone payments totaling $185 million.
Wedbush's analyst has updated their valuation of Edgewise Therapeutics following a significant partnership announcement with Servier. This move reflects the market's reaction to potential future revenue streams and strategic collaborations within the biopharmaceutical sector.